Literature DB >> 17307328

Identification of imatinib mesylate degradation products obtained under stress conditions.

W J Szczepek1, B Kosmacińska, A Bielejewska, W Łuniewski, M Skarzyński, D Rozmarynowska.   

Abstract

In this paper, the decomposition of imatinib mesylate (ImM) under hydrolytic (neutral, acidic, alkaline), oxidative and photolytic conditions was studied. The imatinib mesylate is practically photostable and stable under neutral conditions. The main degradation products under acidic and alkaline conditions are compounds: 4-methyl-N3-(4-pyridin-3-yl-pyrimidyn-2-yl)-benzene-1,3-diamine (2) and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid (3). The main degradation products under oxidation conditions, i.e. 4-[(4-methyl-4-oxido-piperazin-1-yl)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (6), 4-[(4-methyl-1-oxido-piperazin-1-yl)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (7) and 4-[(4-methyl-1,4-dioxido-piperazin-1-yl)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (8), were isolated from the reaction mixtures and identified by the HPLC, 1H NMR and MS techniques. During stress study the suitability of the proposed HPLC method to control purity of the samples was verified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307328     DOI: 10.1016/j.jpba.2006.12.033

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Clinical development of imatinib: an anticancer drug.

Authors:  Dipanjan Goswami; Sanjay Gurule; Abhiroop Lahiry; Amit Anand; Arshad Khuroo; Tausif Monif
Journal:  Future Sci OA       Date:  2016-01-25

2.  Hydrolytic stability of anticancer drugs and one metabolite in the aquatic environment.

Authors:  Michał Toński; Joanna Dołżonek; Piotr Stepnowski; Anna Białk-Bielińska
Journal:  Environ Sci Pollut Res Int       Date:  2021-06-08       Impact factor: 4.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.